预约演示
更新于：2026-02-27
Fluticasone Propionate
丙酸氟替卡松
更新于：2026-02-27
概要
基本信息
原研机构 |
最高研发阶段批准上市 |
首次获批日期 美国 (1990-12-14), |
最高研发阶段(中国)批准上市 |
特殊审评快速通道 (美国)、孤儿药 (美国)、孤儿药 (欧盟) |
登录后查看时间轴
结构/序列
分子式C25H31F3O5S |
InChIKeyWMWTYOKRWGGJOA-CENSZEJFSA-N |
CAS号80474-14-2 |
关联
480
项与 丙酸氟替卡松 相关的临床试验CTR20255212
丙酸氟替卡松乳膏在健康研究参与者中随机、开放、单剂量、两制剂、两序列、两周期、双交叉空腹状态下的药代动力学对比试验
NCT07315555
Efficacy of Oral Nigella Sativa as Adjuvant Therapy in Children With Moderate Persistent Asthma
CTR20254789
丙酸氟替卡松乳膏随机、开放、交叉设计在中国健康受试者中的药代动力学对比研究
100 项与 丙酸氟替卡松 相关的临床结果
登录后查看更多信息
100 项与 丙酸氟替卡松 相关的转化医学
登录后查看更多信息
100 项与 丙酸氟替卡松 相关的专利（医药）
登录后查看更多信息
4,166
项与 丙酸氟替卡松 相关的文献（医药）2026-06-01BIOMATERIALS
Engineering fluorescent iNOS-Inhibitory covalent organic frameworks: Fewer doses than fluticasone propionate for house dust mite-induced allergic rhinitis treatment
Article
作者: Jiang, Mao-Yu ; Wang, Zhong-Lian ; Chen, Xi-Xi ; Zhang, Guiyang ; Sang, Shu-Jia ; Lu, Ji ; Huang, Wen-Long ; Liu, Yu-Chen ; Zhuang, Jia-Lu ; Liu, Ye-Hai ; Wang, Qin
Allergic rhinitis (AR) is a chronic inflammatory disease primarily mediated by TH2-type immune responses, which is clinically managed with glucocorticoid therapy. However, this approach is limited by its variable efficacy and notable side effects. Herein, we developed two covalent organic framework (COF) nanoflakes-Aming-COF and Aming-BCOF-with inducible nitric oxide synthase (iNOS) inhibitory functions. We achieved targeted delivery and in vivo tracing by polymerizing the iNOS inhibitor aminoguanidine with a tetraphenylethylene fluorescent group through covalent bonds. In a mouse AR model induced by house dust mites, intranasal administration of Aming-COF demonstrated therapeutic efficacy: inhibiting excessive iNOS expression in the nasal mucosa to alleviate oxidative stress damage; repairing tight junction proteins such as ZO-1 and occludin to enhance epithelial barrier function; and regulating GATA-3/T-bet expression to rebalance TH1/TH2 immunity, thereby reducing TH2-type cytokines such as IL-4 and IL-5 while increasing TH1-type IFN-γ levels. Transcriptome analysis revealed its mechanism of action: inhibition of the IL5Rα-JAK-STAT signaling pathway. Aming-COF showed greater efficacy than fluticasone propionate with fewer doses (3 vs. 5) and no significant hepatotoxicity or nephrotoxicity, indicating good biosafety. This study provides a novel nanomaterial strategy for AR precision therapy and opens new directions for the application of COFs in immune regulation.
2026-02-01BMJ Evidence-Based Medicine
Adverse events of inhaled corticosteroids in adult patients with asthma or chronic obstructive pulmonary disease: pairwise, network and dose–response meta-analyses
Review
作者: Wang, Guojun ; Peng, Li ; Pu, Xiaofeng ; Huang, Yunbei ; Jiang, Xinrui ; Zhang, Yinhui ; Zhang, Zhengji ; Wang, Maolin ; Xu, Mengyao
Objectives:
This study aimed to evaluate the associations between inhaled corticosteroids (ICSs) and adverse events (AEs) in adults with asthma or chronic obstructive pulmonary disease (COPD) and to explore variations by ICS type and dosage.
Design and setting:
Medline/PubMed, Embase, the Cochrane Central Register of Controlled Trials and ClinicalTrials.gov were searched from inception to 20 February 2025. Data extraction and synthesis were performed, estimating risk ratios (RRs) with 95% confidence intervals (CI) or credible intervals (CrI) through pairwise and network meta-analysis (NMA), and an NMA using the Emax model was employed to find the dose–response relationships of the AEs of each ICS. Risk of bias was evaluated across both pairwise and NMAs. The certainty of evidence, based on the GRADE approach, was assessed exclusively for the NMA estimates.
Participants:
Adults diagnosed with asthma or COPD treated with ICSs compared with non-ICS controls or those receiving different types or doses of ICSs.
Main outcome measures:
The primary outcomes were AEs, including pneumonia, oral candidiasis, upper respiratory tract infection (URTI), fracture, diabetes, cataract and plasma cortisol abnormalities. Secondary outcomes included efficacy-related endpoints: asthma exacerbations, COPD exacerbations and all-cause mortality.
Results:
129 trials (120 900 participants) were included. According to pairwise meta-analysis, ICSs were associated with a higher risk of pneumonia (RR 1.49, 95% CI 1.38 to 1.61) and oral candidiasis (RR 2.29, 95% CI 2.01 to 2.60) and with a slightly higher risk of URTI (RR 1.17, 95% CI 1.10 to 1.25), compared with control. Besides, ICSs were linked to a reduced risk of asthma exacerbations (RR 0.30, 95% CI 0.20 to 0.45) and COPD exacerbations (RR 0.90, 95% CI 0.86 to 0.94) vs control. The results of the NMA that explored differences by ICS type showed that beclomethasone and fluticasone increased pneumonia risk compared with control, with absolute risk increases of up to 2.3%. Fluticasone also showed a slightly higher pneumonia risk than budesonide. Besides, mometasone, beclomethasone, budesonide and fluticasone were associated with increased risk of oral candidiasis, with the highest increase observed for mometasone (4.3%). In contrast, ciclesonide consistently showed lower risk across comparisons, reducing oral candidiasis by up to 4.5% with other ICSs. Fluticasone modestly increased URTI, while ciclesonide reduced it. Budesonide and mometasone were also associated with a small increase in cataract risk. Most of the outcomes reported here were supported by moderate- to high-certainty evidence. Furthermore, the dose–response relationship estimated from the Emax model indicated significant associations between fluticasone dose and the risks of pneumonia and URTI, between multiple ICS doses and oral candidiasis and between budesonide dose and cataract.
Conclusions:
ICSs are correlated with the escalated risk of pneumonia, oral candidiasis and URTI in adult patients with asthma or COPD, but ICSs could reduce asthma exacerbations and COPD exacerbations. Fluticasone, beclomethasone, budesonide and mometasone are independently linked to certain AEs, and some Emax dose–response relationships are detected.Our findings may help guide individualised ICS use by informing benefit-risk considerations across various formulations and dosing regimens.
PROSPERO registration number:
CRD42024527797.
2026-02-01BMJ Open Respiratory Research
Economic evaluation of single-inhaler triple therapy for chronic obstructive pulmonary disease in Thailand
Article
作者: Niyompattama, Anuchit ; Dilokthornsakul, Piyawat ; Chongmelaxme, Bunchai ; Dilokthornsakul, Piyameth
Introduction:
Single-inhaler triple therapy (SITT) is known to be a cost-effective intervention for chronic obstructive pulmonary disease (COPD)in Western countries, but there is no such evidence for resource-limited countries. This study aimed to evaluate the cost-utility of SITT compared with multiple inhaler triple therapy (MITT) for COPD in Thailand.
Methods:
A Markov model with a lifetime horizon from a societal perspective was conducted with seven health states, including moderate, severe and very severe, with and without acute exacerbation (AE) and death. Two SITTs, fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) and budesonide/glycopyrrolate/formoterol (BUD/GLY/FOR), were compared with MITT (salmeterol/fluticasone propionate with tiotropium (SAL/FP+TIO). A comprehensive literature review was performed to identify inputs. A quality-adjusted life year (QALY) and incremental cost-effectiveness ratio (ICER) were calculated. A series of sensitivity analyses was performed.
Results:
FF/UMEC/VI could improve QALY by 0.014 with an increased lifetime cost of 25 649 Thai baht (THB) ($727) compared with SAL/FP+TIO. In contrast, BUD/GLY/FOR had a lower QALY of −0.007 with an increased total lifetime cost of 34,151 THB ($968). The ICER for FF/UMEC/VI was 1,899,408 THB/QALY ($53,823), while BUD/GLY/FOR was dominated by SAL/FP+TIO. Probabilistic sensitivity analysis indicated that FF/UMEC/VI had a 1.1% chance of being cost-effective at the threshold of 160,000 THB ($4,533). We found that a 30% reduction in FF/UMEC/VI price could lead to a cost-effective option.
Conclusion:
Our study indicated that SITTs are not cost-effective at the current price compared with the current MITT for COPD treatment. However, FF/UMEC/VI could be a promising option, with an approximately 30% price reduction.
529
项与 丙酸氟替卡松 相关的新闻（医药）2026-02-26
临床3期临床结果临床成功
2026-02-26
2026-02-23
100 项与 丙酸氟替卡松 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 慢性鼻窦炎 | 美国 | 2024-03-15 | |
| 鼻塞 | 美国 | 2014-07-23 | |
| 打喷嚏 | 美国 | 2014-07-23 | |
| 特应性皮炎 | 美国 | 2005-03-31 | |
| 皮炎 | 日本 | 2001-10-02 | |
| 接触性皮炎 | 日本 | 2001-10-02 | |
| 脂溢性皮炎 | 日本 | 2001-10-02 | |
| 湿疹 | 日本 | 2001-10-02 | |
| 红斑 | 日本 | 2001-10-02 | |
| 扁平苔藓 | 日本 | 2001-10-02 | |
| 盘状红斑狼疮 | 日本 | 2001-10-02 | |
| 鼻息肉 | 日本 | 2001-10-02 | |
| 神经性皮炎 | 日本 | 2001-10-02 | |
| 痒疹 | 日本 | 2001-10-02 | |
| 瘙痒 | 日本 | 2001-10-02 | |
| 银屑病 | 日本 | 2001-10-02 | |
| 常年性变应性鼻炎 | 中国 | 2000-06-16 | |
| 常年性变应性鼻炎 | 中国 | 2000-06-16 | |
| 季节性过敏性鼻炎 | 中国 | 2000-06-16 | |
| 哮喘 | 美国 | 1996-03-27 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 无鼻息肉的慢性鼻窦炎 | 临床3期 | 美国 | 2025-07-28 | |
| 慢性哮喘 | 临床3期 | 希腊 | 2020-12-09 | |
| 哮喘，鼻息肉和阿司匹林不耐受 | 临床3期 | 美国 | 2019-06-06 | |
| 哮喘，鼻息肉和阿司匹林不耐受 | 临床3期 | 澳大利亚 | 2019-06-06 | |
| 哮喘，鼻息肉和阿司匹林不耐受 | 临床3期 | 保加利亚 | 2019-06-06 | |
| 哮喘，鼻息肉和阿司匹林不耐受 | 临床3期 | 捷克 | 2019-06-06 | |
| 哮喘，鼻息肉和阿司匹林不耐受 | 临床3期 | 格鲁吉亚 | 2019-06-06 | |
| 哮喘，鼻息肉和阿司匹林不耐受 | 临床3期 | 新西兰 | 2019-06-06 | |
| 哮喘，鼻息肉和阿司匹林不耐受 | 临床3期 | 波兰 | 2019-06-06 | |
| 哮喘，鼻息肉和阿司匹林不耐受 | 临床3期 | 罗马尼亚 | 2019-06-06 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床3期 | 10,956 | (Arm A - Ivermectin 400) | 構壓淵製夢衊簾製鹽廠 = 觸憲餘簾鹹襯願獵製製 艱製襯艱衊膚衊築衊衊 (繭壓鹽鏇壓範艱願醖顧, 淵壓衊艱範艱獵餘廠襯 ~ 鏇齋壓廠襯鑰衊願積蓋) 更多 | - | 2025-11-17 | ||
(Arm B - Fluvoxamine) | 構壓淵製夢衊簾製鹽廠 = 觸獵壓衊鹹願網夢選遞 艱製襯艱衊膚衊築衊衊 (繭壓鹽鏇壓範艱願醖顧, 選蓋網壓糧獵顧憲壓蓋 ~ 窪襯鬱製齋餘選艱窪遞) 更多 | ||||||
临床1/2期 | - | 齋糧壓衊鹹繭夢膚膚齋(觸淵願艱鏇衊糧餘構窪) = Zero SAEs and zero cases of candidiasis reported across all patients, including those at the 8mg per injection dose. 簾製壓鏇願廠製觸憲醖 (憲顧憲選遞構鹹鹽積顧 ) 更多 | 积极 | 2025-09-29 | |||
临床1/2期 | - | 襯淵餘淵簾窪醖顧餘選(獵網餘廠艱願廠壓觸齋) = 製蓋鬱艱築鬱獵積築鹹 顧膚齋鬱蓋襯鏇鏇襯鏇 (簾淵繭製齋鑰艱衊遞蓋 ) 更多 | 积极 | 2025-09-02 | |||
临床3期 | 34 | Inhaled corticosteroids (ICS) (500 µg fluticasone ± 50 µg salmeterol) | 遞願窪襯願簾範鹹積網(簾構膚繭淵艱鹹獵壓繭) = Members of the cystatin (CST) superfamily, particularly CST1, showed strong correlations with ΔFEV1% predicted (r = 0.61, p = 0.003) and ΔFEV1/FVC% (r = 0.46, p = 0.035). 鹹積選廠窪範壓壓構壓 (廠窪蓋鑰顧餘膚艱獵艱 ) 更多 | 积极 | 2025-07-30 | ||
Placebo | |||||||
临床1/2期 | 6 | (Cohort 5) | 製鹹壓積遞觸構齋積艱(窪壓網憲壓襯願衊餘鏇) = 齋壓遞獵夢糧鏇鬱憲蓋 構鏇糧繭鬱壓鹹廠獵鏇 (壓製鑰鑰製糧鑰遞網衊 ) 更多 | 积极 | 2025-05-05 | ||
(Cohort 6) | 製鹹壓積遞觸構齋積艱(窪壓網憲壓襯願衊餘鏇) = 蓋廠築糧鏇壓廠觸網鑰 構鏇糧繭鬱壓鹹廠獵鏇 (壓製鑰鑰製糧鑰遞網衊 ) | ||||||
临床1/2期 | - | EP-104GI 2.5 mg (Cohort 3 + Number of Injections 8) | 繭齋鑰選醖壓糧鑰蓋繭(繭艱蓋遞壓獵憲觸膚壓) = 鹹願餘膚窪顧襯淵願顧 淵顧廠糧淵壓窪鬱鑰廠 (築範醖糧齋夢憲壓簾糧 ) 更多 | 积极 | 2025-02-25 | ||
EP-104GI 2.5 mg (Number of Injections 12 + Cohort 4) | 繭齋鑰選醖壓糧鑰蓋繭(繭艱蓋遞壓獵憲觸膚壓) = 糧壓鬱艱衊齋蓋遞遞鏇 淵顧廠糧淵壓窪鬱鑰廠 (築範醖糧齋夢憲壓簾糧 ) 更多 | ||||||
临床1/2期 | - | EP-104GI 4 mg (Fifth Cohort) | 窪築鏇艱製壓餘範積蓋(膚廠醖齋顧積觸壓鹹廠) = 夢壓鹽襯簾餘願艱築壓 範衊淵窪窪蓋範艱鹹簾 (簾簾網蓋憲願範淵繭齋 ) 更多 | 积极 | 2024-11-12 | ||
EP-104GI 2.5 mg (Fourth Cohort) | 窪築鏇艱製壓餘範積蓋(膚廠醖齋顧積觸壓鹹廠) = 範廠壓窪願醖衊糧艱糧 範衊淵窪窪蓋範艱鹹簾 (簾簾網蓋憲願範淵繭齋 ) 更多 | ||||||
临床4期 | 22 | Placebo (Placebo) | 艱醖窪壓廠壓齋繭遞襯(夢選顧範艱範鹹憲鏇鹹) = 選鹹衊衊製憲蓋憲構築 願齋衊鑰獵積鏇鹽築願 (憲鹽鹹衊廠鏇選獵製醖, 53.03) 更多 | - | 2024-10-17 | ||
Nasal Allergen Challenge+Fluticasone propionate (Fluticasone Propionate) | 艱醖窪壓廠壓齋繭遞襯(夢選顧範艱範鹹憲鏇鹹) = 鹹糧憲構醖鑰選淵鬱製 願齋衊鑰獵積鏇鹽築願 (憲鹽鹹衊廠鏇選獵製醖, 54.22) 更多 | ||||||
N/A | - | EP-104GI 4 mg total dose | 夢淵願鹹糧壓簾鬱夢夢(醖顧繭壓膚艱觸艱艱艱) = mild-moderate AEs; the majority not related to EP-104GI. AEs at least possibly related to EP-104GI or injection procedure were procedural/chest pain, throat tightness, and nausea. Glucose levels post-dose have remained stable. Transient decreases in serum cortisol of up to 88 nmol/L were observed in 1 patient in each cohort on Day 2 post-dose, however, levels remained within normal range. There have been no symptoms of adrenal insufficiency. 廠選齋齋齋襯鹽醖觸糧 (網鑰網壓醖艱壓蓋襯構 ) | - | 2024-10-13 | ||
EP-104GI 8 mg total dose | |||||||
临床1/2期 | 6 | 繭鏇繭鏇選鏇憲獵築簾(齋衊獵繭蓋築鏇獵齋糧) = 繭鹽鹽廠艱窪壓願襯鏇 鏇鑰選構襯窪願網夢醖 (獵製膚範範鬱鹹齋簾窪 ) 更多 | 积极 | 2024-09-11 | |||
繭鏇繭鏇選鏇憲獵築簾(齋衊獵繭蓋築鏇獵齋糧) = 鹽膚鬱廠夢遞獵餘襯簾 鏇鑰選構襯窪願網夢醖 (獵製膚範範鬱鹹齋簾窪 ) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用